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Abstract 
Glioblastoma multiforme (GBM) is the most common primary central nervous system tumor in 
adults, with an annual incidence of 3.0 per 100,000 of the population. Standard of care is a 
surgical resection of the tumor followed by adjuvant chemoradiation, but this treatment only 
offers patients a median lifespan of 12-18 months.  
We propose an implanted device to deliver therapeutic high frequency electrical stimulation 
within the tumor-affected area of the brain, in a novel approach we refer to as Intratumoral 
Modulation Therapy (IMT). Our study aims to establish the effectiveness of this treatment in the 
F98 Fischer rat glioma model, a preclinical in vivo model of GBM.  
Our data suggests that IMT attenuates tumor growth in vivo, which may result in better outcomes 
for patients with GBM or other tumors of the central nervous system. This may directly translate 
into a desperately needed novel multi-modal paradigm for GBM treatment. 
 
Key Words: Glioblastoma, Electrotherapy, F98 glioma, Fischer rat, Intratumoral Modulation 
Therapy, Thionin staining, Cleaved caspase-3, Stereological analysis, Bioluminescence imaging, 
Magnetic resonance imaging  
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Introduction 
1.1 Glioblastoma multiforme 
Primary brain tumors are responsible for approximately 2.3% of cancer related deaths in 
Europe and North America, and are one of the top ten causes of cancer related 
deaths(Canadian Cancer Society’s Advisory Committee on Cancer Statistics, 2015). 
Gliomas are the most common form of primary brain tumors, and account for 80% of 
malignant central nervous system (CNS) tumors. Gliomas are defined as tumors with 
glial cell origins and include astrocytomas, oligodendrogliomas, and 
ependymomas(Agnihotri et al., 2013). Malignant gliomas are classified by the World 
Health Organization (WHO) into prognostic grades from I to IV based on 
histopathological features and clinical presentation(Louis et al., 2007). The most 
aggressive malignant astrocytoma, glioblastoma multiforme (WHO grade IV), is also the 
most common primary brain tumor and constitutes approximately 54% of all 
gliomas(Ostrom et al., 2013). In North America, the estimated incidence of glioblastoma 
multiforme (GBM) is 3.0 per 100,000 of the population(Louis et al., 2007). The 
prognosis for GBM is dismal, with a median lifespan of 12-15 months after time of 
diagnosis(Stupp et al., 2005).  
In the past decade conventional therapies have failed to produce a meaningful 
improvement in lifespan due in part to the difficulty of developing drugs that can 
penetrate the blood brain barrier. Another challenge is the development of a treatment 
with tumor specificity despite the high intra and inter-tumor genetic and histological 
heterogeneity(Agnihotri et al., 2013; Holland, 2000). 
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1.1.1 Pathological Features 
A GBM tumor mass typically develops in the subcortical white matter of the cerebral 
hemispheres, and is most often found in the fronto-temporal region. Occasionally a GBM 
will diffusely invade through the corpus callosum into the contralateral hemisphere, 
creating a bilateral, symmetrical lesion known as a butterfly glioma. Although GBM is 
exceptionally infiltrative, it rarely invades the subarachnoid space and thus normally does 
not metastasize through the cerebrospinal fluid(Louis et al., 2007). 
GBM is exceptionally histologically heterogenous in nature and displays diffuse and 
rapid infiltrative proliferation of neighbouring brain structures. Grade I astrocytomas are 
benign and have relatively circumscribed borders, whereas grade II astrocytomas are 
characterized by moderate cellularity, little nuclear atypia, and are moderately 
proliferative and invasive. Further, grade III astrocytomas possess increased cellularity, 
nuclear atypia, and mitotic division. Similar to anaplastic astrocytomas (WHO grade III), 
GBM is characterized histologically by the presence of increased cellularity, nuclear 
atypia, and mitotic activity(Agnihotri et al., 2013). GBM is distinguished from lower 
grade astrocytomas by the presence of necrosis and substantial microvascular invasion. 
Moreover, GBM is markedly more aggressive than lower grade astrocytomas, displaying 
a higher rate of proliferation, invasiveness, and angiogenesis(Holland, 2000). 
Depending on the origin of the tumor, GBM can be divided into primary or secondary 
subtypes. These subtypes differ in both their clinical presentation and molecular 
characteristics. Although both subtypes appear indistinguishable at a histological and 
morphological level, they have distinct and notable genetic differences(Agnihotri et al., 
2013).  
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Primary GBM tumors arise de novo, meaning spontaneously, and account for 95% of all 
cases of GBM(Ohgaki et al., 2004). This subtype is characterized by gene amplification 
of epidermal growth factor receptor (EGFR); loss of heterozygosity (LOH) of 
chromosome 10q containing phosphatase and tensin homolog (PTEN); overexpression of 
mouse double minute 2 (MDM2), and deletion of p16(Furnari et al., 2007; Wen & 
Kesari, 2008).  
Secondary GBM tumors account for 5% of GBM cases, are most often found in patients 
under the age of 45, and progress from lower grade astrocytomas into GBM. These 
tumors are characterized by mutations of TP53 and retinoblastoma (Rb); overexpression 
of platelet-derived growth factor A and platelet-derived growth factor receptor alpha 
(PDGFα/PDGFRα), and LOH of 19q(Furnari et al., 2007; Wen & Kesari, 2008). The 
prognosis for secondary glioblastomas tends to be marginally better than the primary 
subtype, although this may be because the average age of diagnosis in secondary GBM is 
younger(Holland, 2000). 
Genomic analysis has revealed four major molecular subtypes for GBM, which have 
been classified as classical, mesenchymal, proneural, and neural. These subtypes are 
distinguished by differential gene expression of EGFR, Neurofibromin-1 (NF1), 
PDGFRα, and ERBB2 respectively. Interestingly, these subtypes have been proven to 
have varying responses to chemotherapy and radiation(Verma, 2009). The vast molecular 
heterogeneity between subtypes has made it exceptionally difficult to find widely 
expressed molecular targets for therapeutics. Further complicating the issue are genetic 
differences found within GBM subpopulations that have been shown to affect patient 
prognosis.  The most common instance of this is the silencing of the DNA repair enzyme 
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O6-methylguanine DNA methyltransferase (MGMT) through methylation of its promoter.  
After receiving radiation and the chemotherapeutic temolozolomide (TMZ), patients who 
have a methylated MGMT promoter live on average 9 months longer than patients 
without the promoter methylation(Agnihotri et al., 2013). 
1.1.2 Epidemiological Features 
GBM can develop at any age, but is most typically found in adults between the ages of 
45-75 years old. A population-based study in Switzerland found the mean age of 
diagnosis is 61.3 years. Over 80% of patients diagnosed were over 50 years old, while 
only 1% of patients were under 20(Louis et al., 2007).  GBM has a slightly higher 
incidence in males than females, with a male:female ratio of 1.26(Ostrom et al., 2013). A 
majority of gliomas appear to have no underlying carcinogenic cause. However, exposure 
to high-dose, ionizing radiation has been established to increase the risk of developing a 
glioma(Bondy et al., 2008; Verma, 2009). The occurrence of glioma in multiple members 
of one family is rare, but seen in approximately 5-10% of glioma cases(Fisher et al., 
2007). Generally, this is observed with inherited tumor syndromes such as Turcot and Li-
Fraumeni syndromes, neurofibromatosis type 1, and multiple enchondromatosis(Bondy et 
al., 2008; Verma, 2009).  
1.1.3 Clinical Presentation and Treatment 
The current standard therapy for newly diagnosed GBM is maximal surgical resection, 
followed by adjuvant chemotherapy and radiotherapy(Nabors et al., 2014). Despite 
aggressive resection, the tumor’s invasiveness and diffuse borders make complete tumor 
resection impossible. In fact, approximately 90% of resected tumors will recur at the site 
of the resection(Berens & Giese, 1999).  
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Despite decades of research, the prognosis for GBM has remained bleak, and overall 
survival in patients has barely improved. Stupp et al.(2005), demonstrated that 
concomitant radiation and chemotherapeutic TMZ, followed by adjuvant TMZ, increased 
median overall survival from 12.1 to 14.6 months compared to radiation alone. 
Consequently, this has become the standard of care for newly diagnosed GBM patients 
following surgical resection(Nabors et al., 2014). 
1.2 Animal Brain Tumor Models 
Animal brain tumor models are necessary to progress our understanding of neuro-
oncology, and to serve as preclinical tests for novel brain tumor therapies. Rat brain 
tumor models have been extensively studied since the 1970s and have been used 
successfully to determine the efficacy of brain tumor therapies(Barth & Kaur, 2009). In 
the 1970s it was reported that brain tumors could be consistently reproduced in adult rats 
by injecting n-Ethyl-Nitrosourea weekly. These tumors were then harvested, cloned, and 
reimplanted into other rats, providing reliable and reproducible models(Barth & Kaur, 
1998).  
Rat tumor models are considered to be most effective when assessing the efficacy of 
therapeutics, whereas mouse models are best suited for elucidating the importance of 
specific cancer related genes(Barth & Kaur, 2009). Mouse tumor models are easier to 
genetically manipulate, letting researchers generate tumors with specific genetic 
alterations and controlled environment influences(Reilly et al., 2008). Rats have a relative 
lack of genetic manipulability compared to mice, and so are less effective when studying 
specific genetic factors. However, rat models have larger brains for more precise 
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stereotactic injections, larger tumor sizes for easier in vivo localization and imaging, and 
more extensive characterization in the literature in vitro and in vivo(Barth & Kaur, 2009). 
Currently, most preclinical brain tumor research uses implantation models. Implantation 
glioma models are much simpler to use and are relatively inexpensive to develop and 
maintain compared to other in vivo models like transgenic models (Lampson, 2001; 
Peterson, Snerioan, Ph, & Brown, 1994). Transgenic tumors are genetically diverse and 
highly variable, and are most well-suited to investigate specific genetic factors underlying 
tumor initiation and progression. Implantation models, where cultured cancer cell lines 
are implanted into an animal, are useful when evaluating the efficacy of a novel 
treatment(Kobayashi, Allen, Clendenon, & Ko, 1980; Lampson, 2001; Peterson et al., 
1994). 
1.2.1 Rat tumor model criteria 
Although no rat brain tumor model will accurately encompass all features of a human 
GBM tumor, it must meet specific criteria to be considered an analogous model. No 
animal model perfectly replicates its human counterpart, but it should be as close as 
possible to reproduce the clinical scenario. For this reason, in a rat glioma model the 
tumor cells must be originally derived from glial cells, and should still be able to grow as 
cell lines in vitro as well as rapidly proliferate in vivo. To produce consistent and testable 
results, the tumor growth rates in the brain should be predictable and reliable. Further, 
these tumors must exhibit the classical pathological features of GBM, should not 
metastasize outside the brain, and should show a similar resistance to treatment as human 
GBM(Lampson, 2001; Mathieu et al., 2007; Peterson et al., 1994; Rama et al., 1986). 
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1.2.2 Rat models of GBM 
A multitude of rat models have been used to study GBM, and they each confer particular 
advantages and disadvantages. Certain models have been particularly well-studied due to 
their ease of use, and similarity to human GBM. The C6 rat glioma model has been 
extensively used in experimental neuro-oncology to assess the efficacy of a wide range of 
conventional and experimental therapeutics(Doblas et al., 2008; Tanriover et al., 2008). 
C6 glioma cells have been molecularly characterized and show changes in gene 
expression similar to human glioblastomas(Guo et al., 2003; Heimberger, et al., 2005). 
However, a major drawback of the C6 glioma rat model is its high immunogenicity in all 
rat strains, due to its origin from outbred Wistar rats(Grobben et al., 2002). Wistar rats 
injected with C6 glioma cells either intracerebrally or subcutaneously demonstrate a 
profound immune response to the tumors(Parsa et al., 2000). The high immunogenicity of 
the C6 glioma model does not accurately reflect the low immune response found in 
human GBM, and thus may overestimate the efficacy of novel therapeutics. Accordingly, 
in vivo studies showing remarkable responses to therapy in the C6 glioma model have not 
translated into human patients(Grobben et al., 2002; Parsa et al., 2000; Tonn 2002). 
Despite this flaw, the C6 glioma model has remained an excellent model to study brain 
tumor biology and has been used to study numerous facets of brain tumor growth and 
proliferation(Li et al., 2013; Miyake, Benadiba, Ribeiro, De Oliveira Silva, & Colquhoun, 
2014). 
Similar to the C6 rat glioma model, the 9L rat gliosarcoma model has been widely used 
to study brain tumors. Unlike human GBM, the 9L gliosarcoma tumor has sharply 
delineated borders and does not demonstrate obvious invasion into the brain 
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parenchyma(Barth & Kaur 2009). The 9L glioma cells were originally derived from a 
Fischer rat brain tumor, and are implanted into syngeneic Fischer rat hosts to test 
therapeutics or investigate tumor cell biology(Barker, Hoshino, Gurcay, & Eliason, 1973; 
Saini, Roser, Samii, & Bellinzona, 2004). Although multiple studies have shown 
impressive therapeutic results using the 9L model, the cells have been confirmed to be 
immunogenic and appear to mediate a T-cell anti-tumor response(Denlinger et al. 1975; 
Morantz et al. 1979). Much like the C6 model, the activated immune system potentiates 
the effect of novel therapeutics and therefore does not accurately reflect the low 
immunogenicity of human glioblastomas(Mcgarrity & Chiang 1995). This has limited the 
use of the 9L model to investigating basic tumor biology(Schepkin et al., 2011).  
The F98 glioma model consists of implanting glioma cells originally derived from a 
Fischer rat, back into syngeneic Fischer rat hosts. F98 tumors show extensive invasion 
into normal brain parenchyma, with groups of tumor cells extending out from the tumor 
mass and forming perivascular clusters(Barth & Kaur 2009). These tumors are 
histopathologically similar to human glioblastomas as they form necrotic cores, contain 
highly mitotic cells, and show non-glomeruloid neovascular proliferation(Mathieu et al., 
2007). Like human glioblastomas, molecular characterization of F98 cells revealed 
overexpression of PDGFβ, and EGFR(Sibenaller et al., 2005).  
This model is considered to be an excellent representation of human glioblastomas 
because it models both the low immunogenicity, as well as the high invasive pattern of 
growth found in humans. The low immunogenicity is critical for evaluating the efficacy 
of novel therapeutic agents, ensuring that most of the tumor cell death is caused by the 
treatment and not the immune system. Further, F98 gliomas in rats have been shown to 
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be unresponsive to systemic chemotherapy and photon-irradiation alone, replicating the 
refractory nature of human GBM(Barth & Kaur 2009; von Eckardstein et al. 2005).  
The F98 glioma model has been widely used in conjunction with MRI to investigate in 
vivo tumor growth in a living rat(Blanchard, Mathieu, Patenaude, & Fortin, 2006). 
Moreover, the F98 cell line can be stably transfected with the luciferase gene to produce a 
bioluminescent cell line(Bryant, Chuah, Luff, Lavin, & Walker, 2008). These cells can be 
implanted into Fischer rat brains, and tumor size and progression can be non-invasively 
monitored by measuring photons emitted by the cells. Consequently, well-established 
multi-modal imaging enables a reliable estimation of therapeutic efficacy.  
In order to compare treatment effect between animals, there is a need for consistent tumor 
take and growth in order to precisely measure therapeutic efficacy. To address this need, 
Mathieu et al (2005; 2007) established an implantation procedure for F98 cells in Fischer 
rats standardizing the number of F98 cells injected, and stereotactic injection coordinate. 
This standardized model of injection resulted in 100% tumor uptake, and demonstrated 
highly reproducible tumor growth. The reproducibility of the F98 model combined with 
its clinical and pathophysiological similarities to human GBM makes it an excellent 
preclinical model to test novel GBM therapeutics.  
1.3 Electrotherapy 
Electrotherapy is a common form of treatment used for certain movement disorders, such 
as Parkinson Disease (PD), and has been used successfully for decades to safely manage 
disease symptoms and improve clinical outcomes(Pereira, Green, Nandi, & Aziz, 2007). 
Recently, electrotherapy has also been explored as an alternative treatment modality for 
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neoplastic disease. Electrotherapeutics have been widely shown to exert anti-tumor 
effects on numerous types of cancer in vitro and in vivo, but the clinical use of 
electrotherapeutics remains uncommon in the treatment of cancer(Guo et al. 2014; Neal 
et al. 2014; Sersa et al. 2015; Tang et al. 2009). The mechanism by which these anti-
cancer electrotherapies work differs based on the intensity and frequency of the electric 
pulses delivered. The effect of electrical stimulation delivered at different parameters to 
cells has been comprehensively studied in the literature(McCaig, Rajnicek, Song, & 
Zhao, 2005). At frequencies under 1kHz, electrical pulses depolarize the cell membrane 
of neurons and can induce action potentials(Repacholi & Greenebaum 1999). High 
intensity stimulation around a kV/cm and high frequency fields in the MHz to GHz range 
generate enough heat to destabilize cell membranes and lead to cell death(Markx, 2008). 
Intermediate frequencies of electric stimulation between 10 kHz and 1 Mhz are too rapid 
to stimulate neurons, and too low frequency to generate significant heat. Accordingly, 
stimulation in this range was long believed to be biologically inert(Giladi et al., 2015).  
1.3.1 Previous electrotherapies to treat GBM 
Electroporation is a form of electrotherapy which has been investigated as a potential 
treatment for GBM. Electroporation entails delivering short bursts of high voltage pulses 
to generate transient, reversible pores in the cell membrane(Gehl, 2003). These pores 
facilitate the uptake of chemotherapeutic agents, in a process termed 
electrochemotherapy, or lead to metabolic instability and cell death. Preclinical in vitro 
studies showed that four to eight electroporating pulses, ranging in intensity from 1000-
1750V/cm, reduced GBM cell viability and increased chemosensitivity. Further, in vivo 
studies demonstrated that eight 400V pulse trains delivered into a rat glioma, 
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concurrently with the chemotherapeutic bleomycin, prolonged animal survival, and 
enhanced gene therapy(Horikoshi, Naganuma, Ohashi, Ueno, & Nukui, 2000; Orlowski, 
Belehradek, Paoletti, & Mir, 1988; Zimmermann, 1982). Despite electroporation’s 
proven efficacy in preclinical models, the extremely high stimulation intensity needed 
affects neoplastic and non-neoplastic cells alike, therefore limiting its usage in a human 
GBM patient.  The potential unintended damage to normal brain parenchyma presents 
unacceptable safety concerns when considering electroporation in a human GBM patient.  
Moreover, the lack of specificity is particularly restrictive if the tumor is diffuse or in 
eloquent regions of the brain(Pudenz, 1976). 
1.3.2 Development of alternating electric fields 
In 2004 Kirson et al., (2004) first investigated the anti-cancer potential of intermediate 
frequency electrical stimulation previously believed to be biologically inert. Human and 
animal cancer cell lines were stimulated at frequencies ranging from 100-500 kHz 
through insulated wires attached to the bottom of cell culture wells. The stimulation 
pulses were staggered between the two electrodes to generate alternating electric fields 
(AEFs), and significantly reduced cell viability across all cell lines tested(Kirson et al., 
2004). Interestingly, different cell lines exhibited varying sensitivities to different 
frequencies. It was found that the optimal frequency to target glioma cells was 200 kHz. 
In both mouse subcutaneous tumors and rat gliomas, AEFs inhibited tumor growth and 
had an additive cytotoxic effect with certain chemotherapies(Kirson et al., 2007). 
1.3.3 Cytotoxic mechanism of alternating electric fields 
The mechanism behind AEFs tumor killing effect is still not completely clear, though 
evidence suggests it is at least partially caused by disruption of charged intracellular 
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molecules responsible for mitosis(Rehman et al. 2015). Mitotic cells contain a 
considerable amount of highly polar microtubules, which form the spindle apparatus 
necessary to undergo normal mitotic division(McIntosh et al. 2002). It is hypothesized 
that AEFs act on these electrically charged molecules by altering their orientation and 
location in the cell, thus disrupting the cellular machinery needed to replicate. 
Microphotography of cancer cells treated with AEFs show abnormalities suggestive of 
aberrant mitosis such as aneuploidy and membrane blebbing in anaphase(Giladi et al., 
2015; Kirson et al., 2004). Further, AEFs have been shown to destabilize microtubule 
formation in dividing cells, thereby increasing the amount of depolymerized tubulin in 
AEF affected cells. This corresponded with a rise in caspase dependent apoptosis, 
ultimately leading to reduced cell viability. Moreover, cytotoxicity was dependent on cell 
doubling time, with faster dividing cells being more susceptible to treatment(Giladi et al., 
2015). This reinforces the theory that the treatment targets cells undergoing mitosis 
exclusively, and would therefore leave post-mitotic cells like neurons unaffected.  
1.3.4 Clinical studies of alternating electric fields 
Due to the promising results in preclinical studies, a pilot study was created for 10 
recurrent GBM patients to receive AEFs in monotherapy. The stimulation was delivered 
by four transducer pads attached to their shaved skull, at 1-2 V/cm and 200 kHz(Kirson et 
al., 2007). These parameters were used as they were previously shown to be the optimal 
frequency to treat gliomas in experimental preclinical trials(Kirson et al., 2004). The 
results seemed encouraging when compared with historical controls, with an increase in 
progress free survival, and overall survival (62.2 vs 29.3 weeks, Kirson et al., 2007). 
However, a follow-up Phase III randomized clinical trial showed a much less favourable 
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response. 237 patients were treated with AEF monotherapy, and 117 were assigned 
physician’s choice chemotherapy(Stupp et al., 2012). There was no statistical difference 
in median overall survival (6.6 vs 6.0 months), progression free survival, radiological 
response rate or one year survival rate. Nevertheless, the external device delivering the 
AEFs is now FDA-approved.  
Despite the negative results, adverse side effects caused by AEFs were reported to be 
significantly lower than in the chemotherapy group, and quality of life questionnaires 
favoured AEFs over the chemotherapy group(Stupp et al., 2012). Recently in a multisite 
randomized clinical trial, adult GBM patients were randomized to receive treatment of 
AEFs and TMZ (n=486) or TMZ alone (n=229). An interim analysis of the trial has 
shown promising results, with a significant improvement for the combined AEF/TMZ 
group compared to TMZ alone in progression free survival (7.1 vs 4.0 months), and 
overall survival (20.5 vs 15.6 months, Stupp et al. 2015). These results, though only 
preliminary, are promising as the life expectancy of patients with GBM has remained 
nearly unchanged in the past decade.  
1.3.5 Limitations of the FDA-approved device delivering alternating electric fields 
Despite these positive results, the largest limitation of the device is achieving patient 
compliance. Due to the externalized nature of the apparatus that delivers the AEFs, there 
is a heavy burden on the patient to ensure the treatment is being delivered effectively. 
Patients must strictly adhere to proper maintenance of management of the device to 
ensure the optimal therapeutic dosage is delivered. Furthermore, the obvious appearance 
of the device coupled with the need to constantly shave one’s head may stigmatize the 
patient and further discourage proper use. Accordingly, patient compliance has been very 
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poor, with more than 20% of patients originally assigned to AEF monotherapy in the 
Phase III trial opting to discontinue treatment earlier than expected(Stupp et al., 2012). 
1.4 Rationale 
Preclinical and clinical data demonstrate significant potential for the use of electrotherapy 
as a new modality to treat GBM, yet existing therapeutics have drawbacks that limit their 
clinical applicability and efficacy. The effectiveness of AEFs may be compromised by 
the inability to precisely target fields to deliver maximum treatment intensity and avoid 
off-target injury. Further, the externalized nature of the device stigmatizes the patient, 
and present an unacceptable burden. Neuromodulation therapy is the delivery of targeted 
low intensity electrical stimulation to the brain through implanted electrodes, and has 
become the surgical standard of care, in the form of deep brain stimulation, for certain 
neurological diseases such as PD. The treatment procedure used in PD is known as deep 
brain stimulation (DBS) and typically entails implantation of a multi-contact lead into the 
subthalamic nucleus or globus pallidus. The lead is controlled by a pulse generator 
located subcutaneously in the chest, which delivers therapeutic low voltage stimulation 
with a frequency of approximately 100-300 Hz(The Deep-Brain Stimulation for 
Parkinson’s Disease Study Group 2001). The mechanism by which DBS works is not 
well-understood, but its effects do not appear cytotoxic to normal brain tissue(Deniau, 
Degos, Bosch, & Maurice, 2010). Our lab has proposed to use an implantable device to 
deliver therapeutic electrical stimulation directly into the tumor-affected region of the 
brain. The stimulation delivered is analogous to the AEFs show to be efficient in treating 
GBM.  This device may exploit the known electrosensitivity of GBM cells, while 
improving the limitations found in other electrotherapeutics. This approach confers many 
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benefits, such as a lack of stigma due to the concealed internalized nature of the device.  
Further, an implanted device permits a more focused, and sustained approach with low 
maintenance for a patient, and the capability to target infratentorial tumours. When used 
in the treatment of neoplastic disease we refer to this approach as intratumoral 
modulation therapy (IMT).  
To date, the effect of IMT has been extensively evaluated by our lab in vitro and found to 
have a selective cytotoxic effect on human cancer cell lines, and primary human GBM 
cells, while not affecting neuronal cell viability (Figure 1, Figure 2). This study aimed to 
develop an in vitro proof of principle model of IMT to investigate any potential anti-
cancer effects of IMT. The IMT model was composed of a central stimulating electrode 
in the center of a 35mm well, and a reference strip electrode around the periphery of the 
well. This electrode configuration permits the therapeutic stimulation to travel in equal 
radial directions outward from the center of the dish, thus encompassing the entirety of 
the well with stimulation. In addition to its selective antitumor effect, IMT appears to 
potentiate the effect of TMZ and gene therapy in vitro, and kill cells in an apoptosis 
dependent manner(Xu et al., 2016). The promising effect of IMT alone, and in 
conjunction with existing and experimental therapies warrants further studies to develop 
the treatment. However, the effect of IMT in a glioma animal model has not yet been 
studied. Although the findings in vitro are encouraging, corroborating these results in an 
animal model would strengthen the evidence supporting IMT. Therefore, determining the 
efficacy and safety of IMT in a living animal is a crucial preclinical step before 
translation of this treatment paradigm into humans.  
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Figure 1. In Vitro model of IMT 
A) Schematic representation of in vitro IMT. Wells fitted with a central stimulating 
electrode and peripheral reference electrodes delivered IMT to GBM cells. 
Primary GBM cultures 48 hours following B) sham treatment (electrode 
apparatus, but no stimulation) or C) IMT, labelled with trypan blue exclusion dye. 
Cells treated with IMT showed reduced cell density, and increased uptake of 
trypan blue dye. Cell viability was assessed using an MTT assay in both D) sham 
and E) IMT treated conditions. F) Mean cell viability was significantly reduced 
after both 24 and 96 hours of IMT (Adapted with permission from Xu et al., 
2016). 
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Figure 2. IMT has no significant cytotoxic effect in post-mitotic neurons 
Brightfield microscopy pictures of embryonic rat neuronal cultures treated for 72 hrs with 
A) sham and B) IMT and exposed to trypan blue dye. No significant changes in cell 
viability or morphology were apparent after IMT compared to sham conditions. C) 
Relative cell viability was measured using the MTT assay. No significant difference was 
found between sham and IMT groups (Adapted with permission from Xu et al., 2016). 
 
 
 
19 
 
 
1.5 Hypothesis 
We hypothesize that an in vivo model of IMT will have a therapeutic effect in the well-
characterized F98 Fischer rat glioma model. IMT has an anti-cancer effect in vitro when 
delivered at the parameters 130 Hz, and 200 kHz.  The parameters for 130 Hz stimulation 
is used in DBS and known to be generally safe, whereas the parameters for 200 kHz are 
supposedly biologically inert and outside the frequency to entrain neuronal activity, and 
therefore will not unwantedly activate neurons. We suggest that IMT delivered at 200 
kHz will have a selective cytotoxic effect on glioma cells, while sparing post-mitotic 
neurons in our in vivo animal model.   
1.6 Objectives 
1. Establish a proof of principle model of IMT in the F98 Fischer glioma model, and 
demonstrate its safety and efficacy. 
2. Through the use of various imaging modalities, establish non-invasive methods to 
evaluate the progression of tumor growth in the F98 Fischer glioma model. 
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Methods 
2.1 F98 Cell Preparation  
F98 rat glioma cells (ATCC, Manassas, VA, USA) were purchased and stored at -20˚C 
until use. The cells were grown in DMEM with 10% Fetal Bovine Serum (FBS), 1% non-
essential amino acids and 1% penicillin/streptomycin (Life Technologies, Carlsbad, CA) 
at 37˚C in a humidified atmosphere of 5% CO2. At approximately 80% confluence the 
cells were passaged using 0.25% trypsin-EDTA (Wisent, Saint-Jean-Baptiste, QC). On 
the day of surgery, cells in their exponential growth phase had their medium removed and 
were washed with PBS two times. The cells were then digested with trypsin-EDTA for 
approximately 5 minutes, before supplemented DMEM was re-added to inactivate trypsin 
activity. The resulting solution was transferred to a falcon tube and centrifuged at 1200 
rotations per minute for five minutes. Another 10 mL of DMEM was added to the 
solution, and then the solution was pipetted up and down repeatedly. The total cell 
number was counted on a cell counter and then washed two more times with PBS. A 
proportionate amount of PBS was then added to make the cell concentration 20,000 cells 
per microliter. Cells in PBS were put on ice and were then immediately transferred to the 
surgery room for injection. 
2.2 Animals and Surgical Procedures 
All procedures followed the guidelines of Canadian Council on Animal Care and Western 
University Animal Care Committee. Approximately 3-6 month old Fischer rats (Charles 
River Canada) were housed in pairs and had food and water provided ad libitum. Rats 
were allowed to habituate to their new environment for at least one week prior to surgery. 
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Rats were anesthetized with 5% isoflurane (University Hospital Pharmacy, London, ON) 
and 2% oxygen, and were transferred to a stereotactic frame. Their heads were stabilized 
in the frame using ear bars and the mouth piece, and they were kept under anesthesia 
throughout the surgery by maintained delivery of 2% isoflurane and 1% oxygen through 
a mouth piece. Body temperature was maintained by an isothermic pad warmed to 
approximately 37˚C. The rats were then shaved at the top of their heads, and the shaved 
area was sterilized with soap, ethanol, and iodine. Rats were administered 0.1mL/100g 
meloxicam and 0.1mL/100g baytril subcutaneously, and a midline scalp incision was 
made in the sterilized area. Bregma was set with stereotaxic units AP: 0mm, ML: 0 mm, 
DV: 0 mm. Three jeweler screws were set into the skull to anchor the head cap. Bilateral 
burrholes were drilled in the skull and cannula/electrode constructs (custom built by 
PlasticsOne, Roanoke, VA) were implanted into the caudate putamen with the 
coordinates AP: 1mm, ML: +/-3mm, DV: 6mm.  
The cannula electrode constructs had an electrode attached to the guide cannula to allow 
infusion of F98 cells through the cannula and subsequent delivery of IMT to the center of 
the tumor. A reference electrode attached to the construct was implanted subcutaneously 
under the nuchal tissue at the caudal end of the incision site. The cannula/electrode 
construct was then secured to the skull with dental cement. Over the course of five 
minutes, two 2µL deposits of DMEM containing 40,000 F98 glioma cells were bilaterally 
injected using Hamilton syringes (Hamilton Company, Reno, NV) connected to an 
injector inserted in the guide cannula via thin plastic tubing (PlasticsOne, Roanoke, VA). 
Injections were performed over a time period of 7 minutes using a micro-infusion pump 
(KDScientific, Holliston, MA) with two operators present. The injectors were kept in 
23 
 
place for two minutes after the injection was completed, to ensure minimal cell backflow. 
Following their removal, the injectors were replaced with sterile threaded dummy stylets 
(PlasticsOne, Roanoke, VA) screwed into the cannula electrode constructs. The incision 
was sutured and 3mL of warm sterile saline was administered subcutaneously.  
After surgery, the animal was monitored in a recovery cage with a heating lamp until it 
awoke from anesthesia, and it was subsequently transferred into a housing cage with soft 
bedding. In order to assess the effect of IMT on normal brain parenchyma, in some 
control animals the entire surgery was performed as detailed above, except no F98 cells 
were injected in either brain hemisphere. In order to establish baseline tumor size at 
various time points after surgery, in some animals the entire surgery was performed as 
previously detailed, but no cannula/electrodes were implanted, and a unilateral 2 µL 
deposit of 40,000 F98 cells was injected by a Hamilton syringe directly into the target 
coordinates.  The baseline tumor size at various time points was also non-invasively 
imaged using MRI and BLI (Table 1). 
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2.3 Initiation of Intratumoral Modulation Therapy 
Four days following surgery, one cannula/electrode construct was randomly chosen to 
receive stimulation, while the other side acted as a sham control. The dummy cap from 
the chosen cannula/electrode construct was removed, and replaced with a connector to 
the stimulation and reference electrode, tethered with a suspended commutator on the 
ceiling of the cage (PlasticsOne, Roanoke, VA) attached to a waveform generator (Rigol, 
China), permitting the animal free range of motion in its cage during treatment. Unilateral 
stimulation (sine wave, 200kHz, +/- 2V) was delivered to the stimulating electrode 
continuously for seven days. Animals receiving IMT did not show signs of distress or 
neurological symptoms while the treatment was being delivered (Figure 3, Figure 4). 
Rigorous quality control safeguards were developed during the course of this thesis work 
to ensure stimulation was appropriately delivered over the time course of the experiment. 
The entire stimulating apparatus was assembled and attached to the waveform generator 
before implantation of the cannula electrode into the rat. The stimulating electrode was 
measured with an oscilloscope to ensure current could flow through the entire apparatus. 
After initiation of IMT, the waveform generator was directly measured with an 
oscilloscope every day to ensure current was still being driven through the apparatus. 
Finally, after termination of the experiment the cannula electrode was extracted from the 
animal and the entire apparatus was re-measured with an oscilloscope to ensure the 
electrode hadn’t been damaged during the course of the IMT.  
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Figure 3. Surgical and therapeutic timeline for in vivo IMT. 
At day 0, electrode cannula constructs were bilaterally implanted into the caudate 
putamen of Fischer rats, and 40,000 F98 cells were injected bilaterally through the 
cannula. Four days were given for tumor growth to occur and to let the rats recover 
before unilateral IMT stimulation began. After 7 days of continuous unilateral stimulation 
animals were sacrificed and brain tissue was harvested for analysis.   
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Figure 4. In vivo IMT apparatus. 
Four days after stereotactic bilateral tumor implantation (see Figure 6) animals were 
unilaterally treated with continuous IMT (frequency: 200 kHz, amplitude: +/- 2V) for 
seven days. The contralateral tumor acted as an intra-animal sham control and did not 
receive treatment. A) Electrical stimulation was produced by a waveform generator 
connected to an implanted electrode in the rat brain. A flexible commutator connects the 
electrodes and waveform generator and permits free movement throughout the cage. B) A 
representative cannula electrode construct to be bilaterally implanted into the striatum. 
The construct is composed of a cannula (dashed arrow) and adjacent electrode (short 
solid arrow), allowing for F98 cell injection followed by stimulation at the epicenter of 
the tumor. A reference electrode (long solid arrow) is implanted outside the skull within 
the nuchal soft tissues. C) Closer view of the animal undergoing IMT. 
27 
 
 
2.4 Brain Extraction and Tissue Sectioning 
Rats were euthanized 4, 7, or 11 days post-surgery. Following an intraperitoneal injection 
of Euthanyl (~0.3 mL, Bimeda, Cambridge, ON), animals were perfused trans-cardially 
with 0.9% saline for 3 minutes, and subsequently with 4% paraformaldehyde (PFA) for 
approximately 7 minutes. Brains were removed and post-fixed in 4% PFA for one hour at 
4°C before they were then transferred to 30% sucrose for approximately three days. 
Brains were sliced in 16µm coronal sections with a Leica cryostat and directly mounted 
onto charged slides (Fisher Scientific, Ottawa, ON). 
2.5 Thionin Staining 
To prepare the tissue for thionin staining, slides were baked at 37°C for 30 minutes, 
rinsed in 0.1M phosphobuffer saline (PBS) for 15 minutes, and then baked at 60°C for 
one hour. The slides were then cleared in xylene overnight. Next, the slides were 
transferred to propanol for 30 minutes, followed by rehydration by two minutes each in 
100, 96, 90, 70, and 50% ethanol. The slides were then transferred to distilled water for 
five minutes, and then stained in thionin for 20 seconds. After rinsing the slides in 
distilled water, the slides were dehydrated by submerging them for two minutes each in 
50, 70, 90, 96, and 100% ethanol. Slides were subsequently differentiated in a solution of 
1mL glacial acid and 250 mL ethanol for 10 seconds, before being transferred to 100% 
ethanol for three minutes, twice. Slides were then transferred to a 1:1 mixture of terpineol 
and xylene for 15 minutes, and then transferred to xylene for 15 minutes, twice. Slides 
were then cover-slipped (Fisher Scientific, Ottawa, ON) using entellan mounting media 
(EMD Millipore, Billerica, MA). 
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2.6 Immunohistochemistry  
Slides were heated at 65ºC for 20 minutes and washed in 0.1M PBS three times for 5 
minutes each to wash off excess cryoprotectant. Slides were permeabilized with 2.5% 
TritonX-100 (Calbiochem, Etobicoke, ON) for 45 minutes and washed 3 times with PBS. 
Slides were incubated in a blocking solution (1% Bovine Serum Albumin, BSA EMD 
Millipore, Billerica, Massachusetts in PBS) for one hour followed by incubation in 
Rabbit-anti-cleaved caspase-3 (1:33, Cell Signalling, Danvers, MA) diluted in 1% BSA 
overnight at 4ºC. Slides were washed with PBS and incubated in AlexaFluor Goat-anti-
rabbit 546 (1:100, Life Technologies, Grand Island, NY) for 1 hour in the dark. Slides 
were washed three times in PBS, and counterstained with 4’-6-diamidino-2-phenylindole 
(DAPI; 1:1000 in PBS, Life Technologies, Grand Island, NY) for 5 minutes. Slides were 
washed three times in PBS and coverslipped with Prolong Gold Antifade reagent (Life 
Technologies, Grand Island, NY). Slides were allowed to dry and then sealed with nail 
polish. 
2.7 Brain Tissue Imaging 
Slides were imaged with a Nikon Eclipse Ni-U upright microscope with an attached DS-
Fi2 high-definition colour camera and imaging software (Nikon Imaging Software-
Elements), and NIS-Elements colour camera (Nikon Instruments, Melville, NY). 
2.8 Stereological Analysis 
A quantitative measurement of tumor size and surface area was obtained using the 
Cavalier estimator on Stereo Investigator software (MBF Bioscience, Williston, 
Vermont) attached to a Nikon Eclipse 90i microscope (Nikon Instruments, Melville, NY). 
Section thickness and number of series per section were input into the program to 
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calculate length between sections. A blinded operator delineated tumor margins rostral to 
caudally to encompass the entire sham and treated tumors. Each tumor outline was then 
merged to generate a three-dimensional (3D) visual representation of the two tumors, and 
a measurement of tumor volume and surface area (Figure 5). 
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Figure 5. Stereo Investigator software. 
A representative section of a tumor undergoing quantification using the Stereo 
Investigator software. The tumor margins of both sham and treated tumors were 
highlighted by a blinded operator. Once the tumor margins for both tumors were 
completely delineated rostral to caudally, the program merged all outlines into 3D 
representation of the tumors. Using the number of sections highlighted, and section 
thickness, the program calculated an approximate surface area and volume for both the 
treated and control tumor. 
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2.9 Bioluminescent Imaging  
Approximately 20,000 F98 cells were transduced with a pre-made commercial lentivirus, 
Redifect Red-Fluc-GFP (Perkin-Elmer, Waltham, MA) at a multiplicity of infection of 
50. Transduction was mediated by the viral transfection agent polybrene (EMB Millipore, 
Billerica, MA). After 24 hours of cell growth the media was replaced with fresh medium. 
Following 48 hours of growth, the cells were thoroughly washed with PBS and then 
suspended using TrypLE (Fisher Scientific, Ottawa, ON). The cells were passaged 
several times, and then sorted twice using fluorescence activated cell sorting (FACS) to 
isolate the highest GFP expressing cells. Sorted cells were pre-stained with 7-
aminoactinomycinD (7AAD) to permit dead cell exclusion. Selected cells were then 
prepared as previously described for striatal injection. 
All in vivo bioluminescent imaging (BLI) was performed using a hybrid optical/X-ray 
scanner In Vivo FX Pro (Bruker Corporation, Billerica, MA). Rats were anesthetized 
with 5% isoflurane and 2% oxygen, and maintained under anesthesia in the scanner with 
a secured nose cone. On days 4, 7, and 11 after surgery rats received 1 mL of the 
luciferase substrate, D-Luciferin, intraperitoneally, and whole body BLI images were 
captured for up to 30 minutes. A signal intensity map, generated by measuring photons 
emitted per second per square millimetre, was used to quantify bioluminescent signal. 
The intensity map was created at every time point to produce a quantifiable visual metric 
for tumor progression.  
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2.10 Magnetic Resonance Imaging  
Imaging at 7 days was performed using a 9.4T small-animal magnetic resonance imaging 
(MRI) scanner (Agilent, Santa Clara, CA). Rats were injected with gadolinium 
intraperitoneally 15 minutes before they were sacrificed, and perfused following the 
previously mentioned protocol. The rat was then imaged. Rats were setup in a custom 
built MRI compatible cradle, and images were acquired using a custom built 
radiofrequency surface coil. The 3 scans acquired were a 2D fast spin echo (FSE) 
sequence, a 3D Flash sequence, and a 3D True FISP sequence. The 2D FSE sequence had 
voxel size 38.4mm by 38.4mm, matrix size 41mm by 0.5mm, TR = 3 seconds, TE = 50 
ms. Flash 3D sequence had voxel size 28mm by 20 mm by 28mm, matrix size 140 mm 
by 140 mm by 140 mm, flip angle = 25°, TR = 40ms, TE = 6ms. 3D True FISP sequence 
had voxel size 28mm by 28 mm by 28mm, matrix size 140 mm by 140 mm by 140mm, 
flip angle = 30°, TR = 7ms, TE = 3.5ms.  
2.11 Statistical Analysis 
SPSS was used for statistical analysis. Data are expressed as group means ± the standard 
error of the means. Student’s one-sample t-tests was used to assess significant differences 
between groups. * indicates statistical difference between group means (p<0.05). 
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Results 
3.1 Tumor progression of F98 gliomas in Fischer rats 
To assess tumor size at commencement of IMT, animals underwent unilateral stereotactic 
implantation of 40,000 F98 cells into the caudate putamen. Separate animals were 
sacrificed after 4 days of tumor growth, at the time when IMT would begin, as well as on 
day 7 and on day 11. Tissue histology revealed robust tumor growth at day 4, with 
invasion into the surrounding brain parenchyma. Tumor size greatly increased by day 7, 
and at day 11 the tumor covered almost the entire area of the caudate putamen. These 
results indicate that IMT is delivered to already robust tumors.
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Thionin stained brain tissue slices 4, 7, and 11 days following a unilateral striatal 
injection of 2µL of PBS containing 40,000 F98 cells. The tumors are highly aggressive 
and proliferative and appear dark purple due to their high cellular density compared to 
normal parenchyma. A) Representative thionin stained sections following 4 days of 
tumor growth in three different rats. B) Representative thionin stained sections following 
7 days of tumor growth in two different rats. C) Representative thionin stained sections 
following 11 days of tumor growth in two different rats. Widespread necrosis is visible 
within the tumors at 11 days.  
 
 
Figure 6. Tumor progression of F98 gliomas. 
36 
 
3.2 IMT attenuates F98 tumor growth  
To model IMT, adult Fischer rats underwent bilateral implantation of cannula electrode 
constructs and were injected bilaterally with 40,000 F98 cells into the caudate putamen. 
At day 4 post-surgery one electrode was attached to the waveform generator, while the 
other acted as a sham control. The waveform generator delivered IMT at a frequency of 
200 kHz and amplitude of +/- 2V for 7 days continuously. After 7 days, the rats were 
sacrificed and their brain tissue was collected and analyzed to determine the effect of 
IMT. Thionin staining revealed a dramatic difference in tumor size between the untreated 
and IMT treated tumors (n=10, Figure 8). Treated tumors appeared larger in size than 
tumors stained 4 days post-surgery, yet smaller than tumors stained 7 days post-surgery, 
indicating a therapeutic inhibitory effect on glioma cell growth.  
When these experiments were conducted, the model was continuously improved and 
refined to increase the reliability of IMT (Table 1). From the animal represented in 
Figure 8G and onwards, a strict troubleshooting protocol was followed to account for 
potential pitfalls that may have limited IMT efficacy and reproducibility. Before surgery, 
the entire apparatus used to generate IMT was assembled, and an oscilloscope was used 
to measure waveform frequency from the cannula electrode tip. This ensured no 
component parts were defective, and the cannula electrode would be able to deliver 
stimulation after implantation. During all 7 days of stimulation, an oscilloscope was used 
to measure waveform frequency directly from the waveform generator output port. After 
the animal was euthanized, the cannula electrode was extracted from the rat scalp and 
plugged back into the apparatus. The entire apparatus was then re-measured with an 
oscilloscope to ensure the electrode was not damaged during the week of treatment. As 
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well, the animal must survive to the end of the time point, and the apparatus must be able 
to deliver stimulation before, during, and after IMT for the animal to be classified as 
receiving the full treatment. After developing these quality control checks, a run of 10 
straight animals received IMT, and then had stereological analysis performed on their 
tumors. Three animals from the group were excluded from analysis: one animal died after 
surgery, and two animals did not receive consistent stimulation deemed adequate to 
represent the effects of IMT. From the remaining animals, histological analysis revealed 
morphological changes in IMT treated tumor shape and size (Figure 9). 
A stereological volume and surface area estimator was used to obtain a quantitative 
measurement of tumor size for all 7 remaining animals in the cohort, which revealed a 
significant decrease in treated tumor surface area and volume when normalized to their 
sham controls (Volume: t=7.662, df=6, p=0.0001). There was no significant decrease in 
surface area or volume in treated tumors when comparing raw data, although there a 
trend was present (Volume: t=1.775, df=6, p=0.063; Surface Area: t=1.795, df=6, 
p=0.0615). Representative 3D models of tumors within the brain parenchyma were 
generated to show the bilateral tumor dimensions of a typical responder and non-
responder to treatment (Figure 10). 
 
38 
 
 
Table 1. Animals used in the study to date 
Experiment Total 
animals 
used 
Experiment 
successful 
Experiment 
unsuccessful 
Reason for failure 
IMT n = 35 n = 10 
 
n = 25 n = 14 (inviable cells did not 
grow robust tumor) 
n = 5 (rat died during surgery) 
n = 3 (rat chewed through 
commutator connection 
disrupting stimulation) 
n = 3 (rat did not respond to 
treatment) 
No stim 
control 
n = 3 n = 3   
4 day control n = 9 n = 3 n = 6 n = 6 (inviable cells did not 
grow a robust tumor) 
7 day control n = 7 n = 3 n = 4 n = 4 (inviable cells did not 
grow a robust tumor) 
BLI n = 2 n = 1 n =1 n = 1 (tumor grew, but BLI 
signal did not appear) 
MRI n = 6 n = 1 (IMT only 
for 4 days) 
n = 1 (7 day tumor 
imaging) 
n = 2 (11 day 
tumor imaging) 
n = 2 (7 day 
tumor imaging) 
n = 2 (inviable cells did not 
grow a robust tumor) 
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Photomicrographs of Fischer rat brain slices treated with sham conditions (left tumor) or 
IMT (200kHz, +/-2V) for 7 days (right tumor). A) Sample rostral to caudal sections show 
a dramatic difference in tumor size between treated and untreated tumors. B-J) 
Representative sections each from a different animal that received IMT demonstrated a 
marked reduction in tumor growth on the treated side. A rigorous quality control protocol 
was developed over the course of experimentation and fully implemented from brains G-
J. 
Figure 7. IMT impedes tumor growth in the F98 glioma model. 
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A-G) Representative photomicrographs of the 7 animals deemed suitable for analysis 
after undergoing 7 days of IMT. Tumors on the right received IMT at previously 
mentioned parameters, while tumors on the left acted as a sham internal control. All 
animals were processed with the same quality control protocol to ensure maximal IMT 
reliability. Each animal responded differently to the treatment, although A,B, and D 
appeared to have marginal to no effect.
Figure 8. IMT cohort of 10 consecutive animals 
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The n=7 animals from Figure 9 underwent stereological analysis to quantitatively 
measure control and treated tumor surface area and volumes. A,B) Histograms reveal a 
significant decrease (p=≤0.0001, p=≤0.0001) in both surface area and volume for IMT 
treated tumors normalized to their sham controls. C,D) Line plots reveal no significant 
difference between control and treated tumor surface area and volume, although a trend is 
present (p=0.0615, p=0.063). Normalized data for surface area and volume were 
compared using a one-tailed, one-sample t-test, and raw data were compared using a one-
tailed paired t-test. Significance is denoted with a * and was chosen to be p<0.05. No data 
were found to be outliers (classified as 3 standard deviations away from the mean).  
 
 
 
* * A B 
Figure 9. IMT significantly reduces treated tumor area and volume relative to its sham control. 
D C 
42 
 
A C 
D B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) Coronal, and B) axial view of a representative responder within the cohort of 10 
animals. The IMT treated tumor is on the right, and is visibly smaller than its control 
Figure 10. 3D modelling of IMT F98 glioma tumors. 
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counterpart. C) Coronal, and B) axial view of a representative non-responder within the 
tested cohort. Both tumors appear to be the approximately same size. 
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3.3 IMT does not change histology of normal brain parenchyma 
Another group of rats received the same bilateral implantation of cannula electrode 
constructs, but did not have any tumor cells implanted. However, these rats were 
stimulated before the rigorous quality control steps were developed and implemented. 
After four days of recovery after surgery, IMT was delivered unilaterally to each rat for 7 
continuous days directly to the normal brain parenchyma (Figure 11). Tumor histology 
show no notable defect on the IMT treated side compared to the control.  
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A-C) Three different control animals received bilateral cannula electrode construct 
implants, but no tumor cell injections and were unilaterally stimulated. D) Rostral to 
caudal slices of a rat with bilateral implants, but unilateral stimulation. For all animals, 
sham conditions are pictured on the left, and electrical stimulation with the same 
parameters as IMT on the right. Asterisks indicate hardware defect caused by the 
implanted constructs; however, there was no notable injury to normal brain parenchyma 
in IMT treated tissue compared to the sham control.  
 
Figure 11. IMT in normal brain parenchyma. 
* 
* 
* * 
* * 
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3.4 Cleaved caspase-3 expression in IMT treated tumors  
Immunohistochemical staining for cleaved caspase-3 revealed expression in the core of 
both the IMT treated and control tumors, but a higher overall expression in the IMT 
treated tumor (Figure 12). However, this pattern of expression was not consistent with all 
treated animals. Cleaved caspase-3 was also heavily expressed in the necrotic core of 
both IMT treated, and control tumors (Figure 13). Activation of caspase-3 to cleaved 
caspase-3 is a key step in apoptosis, and the presence of cleaved caspase-3 is used as a 
marker to indicate the occurrence of cellular apoptosis. Immunohistochemistry without 
the primary antibody did not reveal any non-specific staining (Figure 14).  
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A) Non-treated tumor shows little cleaved caspase-3 activity (red) at the tumor border, 
Figure 12. IMT initiates caspase-mediated apoptosis 
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but increased expression in the core. B) Likewise, the treated tumor from the same animal 
shows little cleaved caspase-3 at the tumor border, and increased cleaved caspase-3 
expression. Staining for cleaved caspase-3 was highest near the centre of both tumors.  
Cleaved caspase-3 signal was much higher in treated tumour than non-treated tumour. 
The dotted white lines delineate the tumor border and beginning of normal parenchyma. 
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A B  
Figure 13. Cleaved caspase-3 expression non-specifically found in tumor core 
 
A) Non-treated tumor shows elevated cleaved caspase-3 activity at the tumor core 
(bottom of image). B) Likewise, treated tumor shows elevated cleaved caspase-3 
expression at tumor core.    
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Figure 14. Cleaved caspase-3 antibody exhibits little non-specific binding 
Staining with no primary antibody for cleaved caspase-3 showed little to no caspase 
activation in both A)sham and B)IMT tumors demonstrating secondary antibody 
specificity.  Treated tumor was stimulated with IMT for 7 continuous days. 
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3.5 Multi-modal imaging to non-invasively track tumor progression 
A pair of animals were injected with F98 cells transfected with the bioluminescent gene 
firefly luciferase. Bioluminescent imaging was chosen as an imaging modality, because it 
is non-invasive, relatively inexpensive compared to other modalities, and easy to 
reproduce. After 4 days of tumor growth, at the time when IMT would begin, as well as 
day 7 and 11, animals underwent bioluminescent imaging if applicable and were then 
sacrificed. Tissue histology and bioluminescent imaging both revealed robust tumor 
growth, with invasion into the surrounding brain parenchyma (Figure 6,15). These 
results indicate that IMT is delivered to already robust tumors, and demonstrate the 
ability to non-invasively measure tumor burden and progression. 
A pilot MRI study was conducted to refine the tumor imaging procedure and observe 
tumor size at day 7 and 11 (Figure 16). Tissue histology was correlated with MRI scans 
at 7, and 11 days to provide more comprehensive modelling of tumor size and shape at 
each time point(Figure 6).  
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Figure 15. Bioluminescent imaging of F98 gliomas. 
Bioluminescence imaging (BLI) of two Fischer rats 4, 7, and 11 days after a unilateral 
striatal injection of 2µL of PBS containing 40,000 F98 cells. The BLI signal is 
concentrated in the region of cell injection, and robust. BLI signal strength dramatically 
increases in intensity over the course of the 11 day period. p/s/mm2; photons, per second, 
per millimetre squared 
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Figure 16. MRI of an F98 glioma after unimpeded glioma growth 7 days post-surgery 
54 
 
T2 weighted MRI image of Fischer rat brain 7 days after unilateral deposit of 40,000 F98 
cells. The rat was sacrificed before imaging, and the brain tissue was harvested 
immediately after the MRI scans. Top to bottom images show axial, coronal, and sagittal 
images of the tumor respectively. Arrows point to substantial peritumoral edema 
surrounding the tumors.  
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Discussion 
IMT has shown promise as a potential treatment for GBM in vitro. Establishing an 
animal model of IMT is a necessary preclinical step before it may be used in humans. 
Here, we established a proof of principle model of IMT in the Fischer rat, and evaluated 
the efficacy and safety of the treatment. We observed a significant reduction of tumor 
surface area and volume in tumors treated continuously for 7 days compared to their 
sham controls. In addition, we found treated tumors had increased expression of markers 
for cell death relative to their sham tumor counterparts. We also visualized tumor 
progression using bioluminescent imaging and magnetic resonance imaging, which may 
be used in the future to non-invasively evaluate the treatment effect of IMT. 
4.1 Assessing tumor progression of F98 gliomas in Fischer rats 
In this study, we found that 40,000 F98 cells injected into the caudate putamen of a 
Fischer rat generated robust tumors only 4 days after injection, and the tumors rapidly 
and aggressively grew throughout the 11 day timeline. The F98 Fischer rat glioma model 
used in this study was based on an established protocol by Mathieu et al, and chosen 
because of its reproducibility and similarity to human GBM(Mathieu et al., 2005, 2007).  
Our first experiments were to assess the progression of the tumor without IMT 
stimulation and therefore no cannula electrodes were implanted. Instead, the rats were 
unilaterally injected with F98 cells through Hamilton syringes. The purpose of evaluating 
tumor histology at 4,7, and 11 days was to ensure tumors grew reliably and at a consistent 
rate throughout the experimental timeline, and determine tumor size at the start of IMT, 4 
days post-surgery. Our data showed that there is substantial tumor growth at 4 days post-
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surgery, and a clear progression of tumor size at 7 and 11 days post-surgery. At the three 
evaluated time points, tumor borders were diffuse and appeared to infiltrate into the 
surrounding parenchyma.  
Studies using the same surgical protocol for the F98 glioma model found similar results, 
although only 10,000 cells were injected so tumor burden was smaller at comparable time 
points(Blanchard et al., 2006). Assessing tumor histology at the 4 day post-surgery time 
point was particularly important, because it marked the initiation of IMT in treated 
animals. Although the 4 day tumor was relatively small compared to its 7 and 11 day 
counterparts, it still represents a sizable tumor mass. Therefore based on corresponding 
histology, IMT in the following experiments was delivered to an already existing tumor 
mass, and not a small deposit of cells. This is more clinically analogous to delivering 
IMT to a tumor mass, rather than an already resected tumor bed. 
4.2 Delivering IMT to normal brain parenchyma 
IMT delivered for 7 continuous days to normal brain parenchyma did not appear to cause 
any tissue damage. The tissue receiving IMT showed no signs of necrosis, bleeding, 
edema, or other damage compared to a sham control within the same brain. This suggests 
that IMT does not have an injurious effect on non-cancerous brain tissue.  However, these 
experiments were performed before the rigorous quality control steps were developed and 
implemented, and therefore should be repeated with the aforementioned steps in place.  
These findings correlate with previously performed in vitro experiments, which showed 
no change in embryonic rat neuronal cell viability after 72 hours of exposure to IMT 
(Figure 2). In this experiment, we performed bilateral cannulation of the cannula 
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electrode construct in Fischer rats following the same protocol as our IMT experiments, 
but crucially we did not inject F98 cells through the cannulas. We then replicated the 
treatment protocol for IMT, delivering unilateral stimulation (sine wave, 200 kHz, +/- 
2V) 4 days after surgery for 7 continuous days, directly into normal brain parenchyma.  
For comparison, a similar study investigating electrochemotherapy in a rat glioma model 
intratumorally delivered 8 high intensity electric pulses (100V, 0.1ms duration, 1Hz) in 
conjunction with 42 IU of bleomycin. The combined treatment was exceptionally 
effective, with 9 of 13 rats that received treatment showing no signs of tumor upon 
termination. To study the effect of treatment on non-neoplastic tissue, the same treatment 
was delivered to normal rat brain parenchyma. The electric pulses caused severe 
morphologic changes in the parenchyma including widespread necrosis, and a substantial 
loss of tissue (Agerholm-Larsen et al., 2011). Although the treatment markedly reduced 
tumor growth in rats, the lack of tumor specificity dramatically limits its potential use in 
humans.  
It is critical that targeted therapies for brain tumors selectively spare surrounding normal 
brain tissue, especially when tumor borders are diffuse or the tumor is in an eloquent 
area(Pudenz, 1976). Therefore, before testing the efficacy of IMT it was important to 
ensure that it was indeed non-harmful to normal brain parenchyma. Overall, we conclude 
that IMT does not cause notable tissue damage in non-neoplastic tissue.  
4.3 Evaluating the effect of IMT on tumor growth compared to internal sham 
controls 
In this study, we found that IMT delivered continuously for 7 days significantly 
attenuates tumor growth compared to internal sham controls. However, the efficacy of 
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IMT varied between animals, ranging from a dramatic to minimal or no response to 
treatment. In vitro IMT parameters were chosen to be similar to DBS (130Hz, 4V, pulse, 
50µs interval), because of the known safety of DBS in non-neoplastic tissue. However, 
the in vivo parameters were based off AEFs, because of their known anti-cancer effects, 
and to escape possible neuronal entrainment at lower frequency levels(Johnson & 
McIntyre, 2008; Kirson et al., 2004, 2007).   
After bilateral cannulation and F98 tumor cell injection, tumors were allowed to grow for 
4 days before initiating IMT (sine wave, 200 kHz, +/- 2V) for 7 days. As previously 
indicated, at 4 days post-surgery a sizable tumor mass had already grown. Nissl staining 
for tissue histology showed a distinct decrease in tumor size in IMT treated tumors 
compared to their sham controls. Treated tumors also showed a change in morphology 
compared to their sham controls. Sham tumors tended to grow in an elongated shape 
along the implanted cannula tract, whereas treated tumors maintained a rounded shape 
with less parenchymal invasion. It has been previously reported in the literature that 
regular untreated F98 tumors grow in an ellipsoid shape(Garcion et al., 2006). The 
change in histological tumor size and shape indicates that IMT reduces tumor 
proliferation and attenuates typical tumor growth, which may offer a prognostic benefit.  
One of the main benefits of IMT compared to other forms of electrotherapy is the ease 
which stimulation can be continuously and directly delivered to the tumor-affected brain 
region. In contrast, AEFs must be delivered directly to the scalp for at least 18 hours a 
day to achieve maximal effect. In fact, a post-hoc analysis of a phase III trial for AEFs 
demonstrated a significantly longer median overall survival in patients undergoing 
treatment for over 18 hours a day (7.7 vs 4.5 months, Mrugala et al., 2014). This may 
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present an unacceptable burden on patients, who are responsible for the maintenance and 
proper usage of the device. A device delivering IMT would be completely implanted, and 
patients would receive therapeutic stimulation constantly without the responsibility of 
maintaining optimal device compliance. Therefore, a series of rigorous quality control 
protocols were developed to ensure IMT was continuously delivered throughout the 
treatment timeline. The entire apparatus used to deliver IMT was fully assembled before 
surgery, and the output was measured with an oscilloscope to guarantee all individual 
components were functional. During treatment, the output from the waveform generator 
was measured every day to confirm stimulation was still being delivered. Further, at the 
end of treatment time point, the cannula electrode was plugged back into the apparatus 
and re-measured with an oscilloscope to ensure the electrode was not damaged during the 
week of treatment. The animal must survive to the end of the time point, and the 
apparatus must be able to deliver current before, during, and after IMT for the animal to 
be classified as receiving the full treatment.  
A cohort of 10 animals was treated with IMT following the aforementioned strict quality 
control steps, and 7 of the animals met the criteria previously set. One of the three 
animals died before initiation of IMT, and the other 2 animals did not meet the standards 
set when measuring current during IMT, and thus were discarded in the analysis. 
Stereological analysis on the remaining 7 rats revealed a quantifiable significant 
reduction in tumor volume and surface area between sham tumors and treated tumors 
normalized to their internal control. This indicates that IMT may indeed attenuate tumor 
growth in the brain. However, there were 3 non-responders in the cohort where IMT 
appeared to have little efficacy.  
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IMT’s occasional lack of therapeutic effect may be explained by the stimulation area not 
covering the entire volume of the treated tumor. Previous studies investigating 
electrotherapies for cancer have shown that the entire tumor must lie within the range of 
the electric field or current for the treatment to have an effect (Gehl et al., 1999; 
Mahmood & Gehl, 2011; Miklavcic et al., 1998, 2010). Minor variations in electrode 
placement within the tumor, or small differences in tumor size at 4 days may have 
resulted in IMT’s treatment effect not extending through the full extent of the tumor. 
Further studies should continue to develop the electrode construct used to deliver IMT, to 
ensure the treatment fully encompasses the tumor margins and provides a more reliable 
response to treatment. 
4.4 The development of quality control measures and optimization of IMT 
Throughout the course of this thesis work, multiple quality control measures were added 
to the IMT protocol, to attempt to reduce variability between animals and treatment. 
Originally, the bilateral injection of cancer cells were performed alone, which may have 
inadvertently led to an operator bias during injections. To counteract this, a second 
operator trained in the surgery would set-up the assembly used for injections and assist 
the first operator with the injections. Although the injections are performed automatically 
with a micro-infusion pump and therefore the opportunity to influence injections is 
limited, the addition of a second operator further minimizes this risk. To further reduce 
bias from injections, the tumor receiving IMT was not decided until the day stimulation 
was initiated.  
Additional steps were taken to increase reliability of the hardware used to deliver 
stimulation. After animals were plugged into the waveform generators for stimulation, 
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there was a notable problem where the wires connecting the commutator to the waveform 
generator would be chewed through. This was because, the connection was mediated by 
two pins taped together, that were unstable and chewable. In collaboration with Dr. 
Michael Jensen and Dr. Eugene Wong in the physics department, a plastic latch was 
attached to the ends of the commutator that could keep the connection between the 
commutator and waveform generator stable.  The latch was eventually used for all of our 
commutators, because of its increased reliability. Before surgery the cannula electrode 
constructs implanted were first attached to the entire stimulation apparatus, and measured 
with an oscilloscope. This ensured that the implanted constructs were functional and able 
to deliver current before surgery.   
When initiating IMT a commutator plugs directly into the implanted cannula in the 
animal’s head. The commutator has two polarized pins that must be plugged in with the 
correct orientation to properly deliver stimulation. Each pin must be measured with an 
oscilloscope to determine which orientation the commutator should be plugged in to 
connect with the central stimulating electrode. As well, during the 7 days of stimulation, 
the waveform generator output was directly measured with an oscilloscope to confirm 
stimulation was still being delivered into the apparatus. Unfortunately, due to the internal 
nature of IMT stimulation, it is not possible to directly measure the output of the central 
stimulating electrode while it is implanted in the brain. However, once the animal 
finished stimulation, the cannula electrode constructs were removed from their scalp and 
plugged back into the apparatus.  This ensured that the electrode was not damaged during 
surgical implantation and stimulation, and current was still delivered through the 
electrode for the 7 days.     
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Despite the implementation of these quality control measures, it appears as if the effect of 
IMT has become less dramatic over the course of experiments. It is likely that the results 
obtained after the measures were implemented are a more reasonable approximation of 
IMT’s effect, due to the reduced variability and increased rigor involving tumor 
implantation. Variability of treatment effect may exist between animals due to differences 
in the microenvironment surrounding the electrode, such as a blood vessel or substantial 
edema. This may affect the strength and spatial dimensions of the treatment and lead to 
differences in tumor response to treatment. It is unclear why treatment effect was more 
moderate after implementation of quality control measures, though it is possible that 
treatment effect was originally overrepresented due to inadvertent biases that were 
controlled for with optimization. 
4.5 Cleaved caspase-3 expression in IMT treated tumors compared to sham 
controls 
In this study, we found higher cleaved caspase-3 immuno-labelling within treated tumors 
compared to their sham controls. Once cleaved, caspase-3 acts as an executioner protein 
that irreversibly commits a cell towards apoptosis, and thus is used as a hallmark of 
apoptosis(Elmore, 2007; Janicke, Sprengart, Wati, & Porter, 1998; Porter & Janicke, 
1999). The presence of cleaved caspase-3 in treated tumors indicates that IMT may 
trigger glioma cells to undergo apoptosis, leading to a decrease in tumor proliferation. 
This correlates with previous in vitro IMT results showing an increase in cleaved 
caspase-3 immuno-labelling after 72 hours of treatment(Xu et al., 2016). However, the 
exact mechanism by which IMT induces apoptosis is still unclear.  
64 
 
Although the precise mechanism of AEFs are unknown as well, they have been shown to 
significantly increase apoptosis after 48 hours of stimulation. Interestingly, pan-caspase 
inhibition in combination with AEFs returned the level of apoptosis to control 
levels(Giladi et al., 2015). This suggests that the cell death caused by AEFs is mediated 
by caspase activation. Ultimately, this appears to be caused by destabilization of tubulin 
subunits within microtubule structures, leading to aberrant cell division and aberrant 
chromosome segregation(Davies, Weinberg, & Palti, 2013; Giladi et al., 2015; Pless & 
Weinberg, 2011; Turner, Gergel, Wu, Lacroix, & Toms, 2014).  
Paclitaxel, an anti-cancer drug that prevents microtubule disassembly, causes cell death 
by disrupting microtubule activity, leading to aneuploidy and aberrant chromosomal 
segregation(Giladi et al., 2015; Lanni, Lowe, Licitra, Liu, & Jacks, 1997; von 
Eckardstein et al., 2005). This supports the idea that microtubule disruption can cause cell 
death by inducing mitotic dysfunction. However, further investigation is required to 
better understand IMT’s effect on intracellular structures, and the precise mechanisms by 
which it induces cell death. 
We also found elevated levels of cleaved caspase-3 within the core of treated tumors and 
their sham controls. Gliomas proliferate rapidly, and often cannot maintain adequate 
vascularization throughout the entire tumor to provide oxygen and nutrients.  This 
ultimately leads to a hypoxic tumor core, causing necrosis and apoptosis at the center of 
the tumor(Martínez-González, 2012).  High levels of apoptosis may be found at the 
center of both treated and untreated tumors, and therefore using an apoptotic marker may 
not be the most effective method to evaluate cell death caused by treatment.      
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4.6 Multi-modal non-invasive imaging to track progression of F98 gliomas in 
Fischer rats 
In this study, we established MR and BL imaging for our F98 rat glioma model, which 
will be used in the future to non-invasively track the therapeutic efficacy of IMT over 
time. Both MRI and BLI are well-established in the F98 model, and are excellent 
techniques to non-invasively evaluate tumor progression(Towner et al., 2013). When 
measuring the efficacy of a novel treatment like IMT, it is essential to quantify the effect 
of treatment throughout tumor progression.  
In humans, MRI is an important diagnostic tool to provide information to clinicians on 
tumor volume and location. In a preclinical rodent model, MRI permits 3D tumor volume 
measurements, and includes the necrotic core to include in overall volume 
calculations(Blanchard et al., 2006). In BLI, tumor cells are tagged with a luciferase 
reporter gene before implantation, to allow for visualization of only metabolically active 
tumor cells. This generates an image of only tumor cells, without including edema or 
other inflammatory regions that may be seen on MRI. As well, the process itself is much 
more cost-efficient compared to an MRI. The amount of radiance emitted from the tumor 
can be readily measured and quantified, which permits measurement of tumor size and 
progression at different time points. However, the image generated is 2D and thus cannot 
be readily be used to calculate tumor volume(Bryant et al., 2008; Hashizume et al., 
2010).   
Here we have correlated tumor histology with MRI and BLI, after unilateral implantation 
of 40,000 F98 cells. In both imaging modalities we found a corresponding increase in 
tumor size, and metabolic activity over the experimental time point. Comparing the 
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histology to the imaging gave us a baseline level of expected tumor growth in an 
untreated rat. These quantifiable images will ultimately be compared to rats treated with 
IMT, to provide an objective measurement of the treatment effect. Using both MRI and 
BLI will allow for the measurement of change in both tumor morphology and structure, 
as well as metabolic activity. This may prove useful to thoroughly evaluate the efficacy 
of IMT, by providing a more well-rounded approach to assessing treatment 
effect(Kirschner et al., 2015). 
4.7 Study Limitations 
One limitation in this study is the lack of understanding of the mechanism by which IMT 
works. Further investigation is required to better understand the underlying cause leading 
to in vitro GBM cell death, and in vivo attenuation of tumor growth. Depending on the 
mechanism, stimulation parameters and the delivery of the treatment can be altered to 
best enhance treatment efficacy. Better understanding the mechanism of action may also 
reveal currently undetectable side effects, or synergistic drugs that can amplify IMT’s 
tumor killing effect.  
As well, a limitation in our study is that the area of electric field generated by our IMT 
set-up has not been determined. Although calculating the precise electric field dimensions 
of IMT may be difficult, mathematical simulations have been successfully used to assess 
the electric field range of AEFs(Lok, Hua, & Wong, 2015). Understanding the effective 
electric field range of IMT is critical, because IMT must encompass the entire tumor to 
increase the likelihood of a response to treatment. Other forms of electrotherapy tested 
intracranially have had poor effect when the entire tumor was not in the range of 
treatment(Agerholm-Larsen et al., 2011). This may account for variability in treatment 
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found in IMT, because tumors may occasionally be out of the range of treatment and then 
grow uncontrollably.  
Another limitation is the current construct apparatus used to deliver IMT intratumorally. 
Currently the cannula and electrode are combined into one construct, to permit 
stimulation directly in the tumor epicentre following F98 cell implantation. However, the 
apparatus can be simplified to reduce confounding factors, by eliminating the need for a 
cannula. Instead, a Hamilton syringe could stereotactically inject cells into the coordinate, 
followed by implantation of an electrode construct. The construct would be similar to the 
one currently used, but without a cannula attached. This would eliminate the large tissue 
defect caused by the cannula. Further, the cannulas are made of stainless steel, which has 
been shown to attenuate electric field strength (Prato et al., 2013). It is possible that the 
cannula’s presence lessens the electric field delivered to the tumor and weakens the effect 
of IMT. Therefore, simplifying the implanted device may dramatically increase treatment 
effect. 
Finally, another potential limitation in our study is the quantification of tumor volume 
measurements using stereology. This is because the calculated volume does not take into 
account or distinguish between necrosis and the lesion created by the cannula electrode 
construct. Since the volume of the tumors is not solid all the way through, stereological 
analysis may overestimate the overall tumor volume. Tumor surface area may therefore 
be a more accurate measure to evaluate tumor size. However, when comparing IMT 
treated tumors to internal controls, there did not appear to be a notable difference 
between reductions in surface area and volume.  
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4.8 Future Directions 
In our study we demonstrated that IMT attenuates tumor growth in a rat glioma model, 
and established tumor imaging modalities in our model to non-invasively track tumor 
progression. A critical next step in developing an animal model of IMT is to 
mathematically model the electric field generated by the stimulation. As previously 
mentioned, the precise spatial dimensions of IMT’s electric field have not been 
investigated. If the current set-up generates a small and focal electric field, then the entire 
tumor may not receive the treatment effect. It is essential to further investigate the 
electric field size with different stimulating and reference electrode configurations to 
ensure the entire tumor margins are encompassed by the treatment. The electric field 
intensity and spatial dimensions may change depending on the location and number of 
stimulating and reference electrodes(Agoramurthy, Campana, & Sundararajan, 2011). 
Ultimately, modelling the electric field generated by IMT will permit further optimizing 
of the electrode configuration. This may lead to greater efficacy and reproducibility of 
IMT in vivo. 
Currently, the standard of care for treating GBM is surgical resection of the tumor 
followed by adjuvant chemotherapy and radiation. IMT may serve as a new modality of 
treatment to be offered alongside existing therapies. Our lab has already shown IMT 
markedly enhances the effect of the chemotherapeutic TMZ in vitro(Xu et al., 2016). The 
F98 glioma model in Fischer rats has been proven to be resistant to conventional forms of 
therapy, much like human GBM(Hayat, 2011). Combining IMT with already existing 
therapies may potentiate overall treatment efficacy, without worsening side effects and 
patient quality of life. Future studies will investigate the clinically relevant combination 
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of IMT, TMZ, and radiation in the F98 glioma model to evaluate any potential synergistic 
or additive effects between IMT and existing therapies. As well, any potential negative 
side effects or interactions between treatments will be investigated. 
Another potential study is a longitudinal experiment assessing the effect of IMT over an 
undefined period of time. Instead of bilateral tumor implantation, there would only one 
tumor implanted per animal. A cohort of animals would receive IMT, while another 
cohort would receive no treatment. Therefore, an internal control tumor is unnecessary, 
because the two groups would be compared to each other rather than two tumors in a 
single animal.  Further, adding an internal untreated control tumor would shorten the 
lifespan of animals in both groups, and confound the potential lifespan enhancing effects 
of IMT. Unlike our current experimental paradigm, animals would not be sacrificed until 
they reached a predetermined health threshold. Ideally, the study would demonstrate a 
decrease in tumor growth due to IMT, correlated with a corresponding increase in 
lifespan. Additionally, this study could include the conventional therapies previously 
mentioned to assess the effect that combined therapy has on overall animal lifespan. 
These studies would be complemented by monitoring tumor progression with both BLI 
and MRI to quantify the change in tumor size over the experimental timespan. 
Demonstrating a quantifiable and measurable increase in lifespan with IMT would be a 
promising step towards the use of this treatment in the clinic. 
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PART 5: SUMMARY AND CONCLUSIONS 
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Summary and conclusions 
5.1 Summary 
 40,000 F98 cells implanted into the caudate putamen had reproducible growth 
kinetics at the 4, 7 and 11 day post-surgery date, with robust tumors 4 days post-
surgery 
 IMT delivered directly to normal brain parenchyma did not cause tissue damage, 
necrosis, or bleeding  
 Tumors treated with IMT for 7 continuous days had altered morphology and were 
smaller in size than their internal sham controls 
 IMT treated tumors had significantly decreased surface area and volume when 
normalized to their sham control.  
 BLI and MRI non-invasively offers the capability to measure the progression of 
F98 tumors in Fischer rats over the experimental time point. 
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5.2 Conclusion 
This study established a proof of principle model of IMT in the Fischer rat glioblastoma 
model, and investigating the safety and efficacy of the treatment. Our findings indicate 
that 7 days of continuous IMT stimulation does not cause damage to normal brain 
parenchyma. However, we showed that 7 days of continuous IMT stimulation delivered 
to intracerebral gliomas attenuates tumor growth. Histological analysis of brain tissue 
indicated that treated tumors were smaller in size compared to their internal sham 
controls. As well, stereological analysis of treated tumors revealed a significant decrease 
in tumor surface area and volume, when normalized to their internal sham controls. 
Further, we successfully monitored tumor progression in our model using the non-
invasive imaging modalities BLI and MRI. 
This study builds on the comprehensive in vitro experiments previously performed that 
established the anti-cancer properties of IMT. With emerging evidence supporting the use 
of electrotherapy for GBM, it is crucial that this animal model of IMT continues to be 
optimized and developed. These results will guide further studies to enhance the efficacy 
and reproducibility of IMT, and will serve as a crucial step before clinical translation. 
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